SlideShare a Scribd company logo
1 of 5
Download to read offline
RETAIL RESEARCH Page | 1
HDFC sec Scrip code Industry CMP (Rs.) Recommended Action Averaging Price Band (Rs.) Target (Rs.) Time Horizon
MARINDEQNR FMCG 265.4 Buy at CMP and add on dips 238‐248 295 1 quarter
In our Q4FY14 Result Update dated May 10, 2014, we had recommended investors to buy Marico on dips to Rs. 214‐223 for a price target of Rs. 248 over the next
quarter. Thereafter the stock touched a low of Rs. 222.1 on May 20, 2014 and subsequently met our price target on May 27, 2014. It touched a new high of Rs. 294.5 on
Aug 05, 2014. Currently, it is quoting at Rs. 265.4.
Marico’s ex Kaya numbers for Q1FY15 were above our estimates on the revenue front, while operating profit & PAT growth were in line. We present an update on the
stock:
Q1FY15 Results Review (Consolidated – Ex Kaya)
Y‐o‐Y
• The consolidated net sales increased by 25.2% to Rs. 16192.4 mn, driven by price hikes taken across the portfolio to cover a major part of the input cost push. Volume
growth stood at 5%. The domestic consumer product business grew by 28% with volume growth of 6.5%. Parachute’s rigid portfolio (packs in blue bottles) recorded
value growth of 41%, with volume growth of 6% (lower than 10% volume growth reported in Q4FY14, but better than 4% growth in Q1FY14). Saffola grew by 14%,
largely driven by healthy volume growth of 10%. Value added hair oil (VAHO) grew by 28%, with volume growth recovering to 11% (compared to 5% in Q4FY14 & 8%
volume growth in Q3). However, Paras brands disappointed with flat revenue growth. The company registered market share gains in more than 80% of the portfolio.
• International business posted growth of 16.3% aided by 6.7% translation gains. Constant currency growth stood at 9.6%. Growth in the Core markets remained healthy
with Bangladesh growing at 14%, MENA at 18% and South Africa at 9% on constant currency basis. However, Vietnam remained flat during the quarter.
• Gross margins fell sharply by 382 bps Y‐o‐Y to 45.2% on the back of steep rise in copra prices (up 131% Y‐o‐Y). Also, the market prices of liquid paraffin were 14%
higher Y‐o‐Y. However, fall in EBITDA margins was limited at 70 bps Y‐o‐Y to 16.5%, aided by relatively lower growth in A&P cost & other expenses (up 13% & 11.1%
respectively). On absolute basis, the operating profit increased by 20.1% Y‐o‐Y.
• PAT grew by 19.5% Y‐o‐Y, impacted by higher tax rate (up 253 bps Y‐o‐Y) & higher depreciation cost (up 27.3% Y‐o‐Y). PAT margins fell by 55 bps Y‐o‐Y to 11.4%. EPS
for the quarter stood at Rs. 2.9 vs Rs. 2.4 in Q1FY14.
Q‐o‐Q
• Sequentially, the results were impressive. Net Sales grew by 51.4%, while operating profit rose 72.8% Q‐o‐Q, aided by relatively lower growth in employee & A&P cost
(up 31.2% & 9.8% Q‐o‐Q respectively). OPM increased by 205 bps Q‐o‐Q from 14.4% in Q4FY14.
• PAT grew by 108.7%, aided by marginal growth in interest cost (4.3% Q‐o‐Q, decline in the depreciation expense (down 5.5% Q‐o‐Q) & lower effective tax rate (down
770 bps Q‐o‐Q). PAT margins improved by 315 bps Q‐o‐Q from 8.3% in Q4FY14.
RETAIL RESEARCH Aug 11, 2014Marico Ltd. – Q1FY15 Result Update
RETAIL RESEARCH Page | 2
Quarterly Financials: Consolidated (ex‐ Kaya)
(Rs. in Million)
Particulars Q1FY15 Q1FY14 VAR [%] Q4FY14 VAR [%] Remarks
Net Sales 16192.4 12930 25.2 10698.2 51.4
• The overall growth was driven by price hikes taken across the portfolio to cover a major
part of the input cost push. Volume growth stood at 5%. The domestic consumer product
business grew by 28%, led by strong value growth in Parachute and VAHO (up 41% & 28%
Y‐o‐Y respectively.
• International business grew by 16.3% aided by 6.7% translation gains. Constant currency
growth stood at 9.6% with healthy growth (in CC) across key markets like Bangladesh (up
14%), MENA (at 18%) and South Africa (up 9%).
Other Operating Income 38.9 30 29.7 22.4 73.7
Total Operating Income 16231.3 12960 25.2 10720.6 51.4
Total Expenditure 13564.8 10740 26.3 9177.9 47.8
Raw Material Consumed 7863.9 5580 40.9 6005.3 30.9
The material cost to net sales rose 383 bps Y‐o‐Y & 271 bps Q‐o‐Q to 55%. Gross margins
fell sharply on the back of steep rise in copra prices (up 131% Y‐o‐Y). Also, prices of Liquid
Paraffin were up 14% Y‐o‐Y.
Stock Adjustment 730.9 740 ‐1.2 ‐697.1 ‐204.9
Purchase of Finished Goods 316.1 300 5.4 289 9.4
Employee Expenses 854.5 730 17.1 651.3 31.2
Advertisement & Sales Promotion 1921.8 1700 13.0 1219.1 57.6
ASP cost / Net Sales fell by 128 bps Y‐o‐Y, but rose 47 bps Q‐o‐Q to 11.4%. The Y‐o‐Y fall
was due to high inflation led topline growth. The Company expects to operate in a band of
11‐12% in the medium term.
Other Expenses 1877.6 1690 11.1 1710.3 9.8
Operating Profit 2666.4 2220 20.1 1542.7 72.8
Other Income 183.2 140 30.9 128.4 42.7
Interest 70.4 100 ‐29.6 67.5 4.3
PBDT 2779.3 2260 23.0 1603.6 73.3
Depreciation 203.7 160 27.3 215.5 ‐5.5
Y‐o‐Y rise in depreciation cost was due to adoption of the useful life of fixed assets as per
Schedule II of Companies Act 2013, effective April 1, 2014 (Rs.2.65 cr), fixed asset additions
made during the year and impairment of fixed assets in Egypt and Bangladesh.
PBT 2575.5 2100 22.6 1388.1 85.5
Tax (incl. DT & FBT) 678.5 500 35.7 472.6 43.6
The effective tax rate on PBT increased by 253 bps Y‐o‐Y, but fell by 770 bps Q‐o‐Q to
26.3%. The Y‐o‐Y rise in the ETR is primarily due to one of the factories in India going out of
tax exemption and another is moving into 30% exemption bracket from 100% exemption.
Also, from this year, there has been an increase in tax rate in Vietnam. The expected ETR
during FY15 and FY16 could be around 28‐29%.
PAT (before minority interest) 1897.0 1600 18.6 915.5 107.2
Minority Interest 44.2 50 ‐11.5 27.9 58.6
PAT (net of minority interest) 1852.8 1550 19.5 887.6 108.7
Y‐o‐Y PAT growth was lower than the sales growth, impacted by lower OPM, higher
depreciation cost & higher effective tax rates.
RETAIL RESEARCH Page | 3
EPS (Rs.) 2.9 2.4 19.5 1.4 108.7
Equity 644.9 644.8 0.0 644.9 0.0
FV 1.0 1.0 0.0 1.0 0.0
OPM (%) 16.5 17.2 ‐4.1 14.4 14.2
EBITDA margins contraction was limited at 70 bps Y‐o‐Y to 16.5%, helped by relatively
lower growth in A&P cost & other expenses. While the overall margins contracted, the
OPM of international business improved by 490 bps to 18.2% reflecting a structural shift in
international margins based on the cost management projects undertaken last year.
PATM (%) 11.4 12.0 ‐4.5 8.3 37.9
(Source: Company, HDFC sec)
Other Developments / Highlights
• The non‐focused part of the parachute portfolio (pouch packs) witnessed de‐growth as input prices faced inflationary pressures while the Company maintained
minimum threshold margins. It is generally observed that an inflationary environment swings the competitive position to the Company's advantage as it puts pressure
on the working capital requirements of marginal players. During the 12 months ended June 2014, Parachute along with Nihar increased its market share by 50bps to
56%. Parachute's share in the rural markets, in the range of 35‐40%, is lower than that in the urban markets, thus providing potential headroom for growth.
• Market share of Saffola declines 200bps Y‐o‐Y to 55%, thus indicating increased competitive intensity. However, Saffola Oats has emerged as a strong no.2 brand in the
oats category with a value market share of 17%. Two sweet flavours with fruits were introduced to compliment the bouquet of six savory flavors. Focus on value added
offerings in the oats segment has enabled the Company to capture 51% share in the flavored oats market. The Company launched a new campaign on Masala Oats this
quarter, the initial response to which has been very positive. The Company expects to reach a top line of ~Rs 70‐75 crore (USD 12‐13 mn) in this fiscal for the franchise
and is poised to cross Rs. 1 bn (USD 17 mn) landmark next year.
• In VAHO, the company continues to grow faster than the market and has emerged as a clear market leader with 28% share (for 12 months ended June 2014) as against
27% during the same period last year. Nihar Shanti Amla continues to gain market share and achieved a volume market share of about 30% for the 12 months ended
June 2014 in the Amla hair oils category (MAT Q1FY14: 27%).
• Sales in Modern Trade (9% of the domestic turnover) continued its good run and grew by 27%. Rural growth (33% Y‐o‐Y) continues to outperform urban (25% Y‐o‐Y) as
rural now contributes 30% to total domestic sales.
• As per the management, its key focus in the current scenario would be on improving volume growth over profitability. It has guided for 7‐8% volume growth and 14.5‐
15% EBITDA margin band for FY15 though it expects next two quarters to witness margin pressure on account of sustained copra inflation.
• Due to a spurt in copra prices from mid‐2013 onwards, the company has initiated a series of price increases. A weighted average price increase of 19% over Q4FY14
was taken during the quarter. This, coupled with price increases taken last year, has led to a weighted average price increase of 33%. The given price increases would
partially offset the rise in copra prices.
• The company plans to double its revenues over the next four years driven by a mix of organic and inorganic growth. It plans to become an emerging market MNC with
focus on Asia and Africa in key categories of hair care, skin nourishment and male grooming. It has identified give key areas of transformation—innovation, GTM,
Talent Value Proposition, IT & Analytics and Cost Management.
RETAIL RESEARCH Page | 4
Conclusion & Recommendation:
Marico’s ex Kaya numbers for Q1FY15 were above our estimates on the revenue front, while operating profit & PAT growth were in line. The growth was largely led by
price hikes taken across the portfolio to cover a major part of the input cost push. Volume growth stood at 5%. Strong growth in domestic consumer product business (up
28% Y‐o‐Y, aided by strong value growth in parachute and VAHO) and decent growth in international business revenues (led by double digit growth in Bangladesh &
MENA) despite challenging environment was encouraging. Further, the volume growth recovery in domestic business witnessed in Q4FY14 was sustained in Q1FY15
despite challenging environment (though in single digits). On the profit front, while the sharp contraction in gross margins (down 382 bps Y‐o‐Y), impacted by steep rise in
copra prices was discomforting, the overall OPM contraction was limited (at 70 bps Y‐o‐Y), aided by relatively lower growth in A&P cost & other expenses.
We expect volume growth of Parachute (rigid pack) to improve gradually from 6% (which was healthy in our view considering steep rise in copra prices) to 7‐8% in the
coming quarters, likely to be driven by conversion from loose coconut oil to branded coconut oil and rural market share gains. We feel that an inflationary environment
swings the competitive position to the company’s advantage as it puts pressure on the working capital requirements of marginal regional players. This leads to market
share gain and better volume growth. While volume growth recovery in VAHO (compared to Q3FY14 & Q4FY14) is encouraging, its sustainability is essential. With
company’s efforts to increase the distribution reach in rural market and shift in consumer preference towards living a healthy lifestyle, we expect Saffola’s volume growth
to remain healthy in double digits (expected to improve gradually from 10% currently).
Sharp rise in the Copra prices would continue to put pressure on Marico’s overall gross margins in near to medium term. However, price hikes initiated in parachute
(weighted average price increase of 33% Y‐o‐Y) and in VAHO (weightage average price hikes of 6% Y‐o‐Y across portfolio) would restrict a sharp deceleration in margins.
Further, cost rationalisation would limit the contraction in OPM in FY15. However, we expect gradual uptick in margins in FY16, since we expect stability in Copra prices.
We feel Marico could surpass our revenue estimates in FY15. Hence we are enhancing the same by 4.9%. However, it seems to be on track to meet our operating profit &
PAT growth. Hence we are keeping the same unchanged (since margins could be lower than our expectations). We have incorporated projections for FY16, wherein we
expect net sales, operating profit & PAT to grow by 16%, 19.7% & 20.8% respectively.
At the CMP, Marico trades at 25.7xFY16E EPS. Sustained improvement in the volume growth (which is a key driver for sustainable profit growth), market share gains &
profitability could result in gradual re‐rating in the stock price in the coming quarters. Valuing the stock at 28.5xFY16E EPS we arrive at a price target of Rs. 295. We feel
investors could buy the stock at current levels and average it on dips to Rs. 238‐248 (23‐24xFY16E EPS) band for our price target over the next quarter.
Financial Estimations: (Consolidated) ‐ excluding Kaya.
(Rs. in Million)
Particulars FY13 FY14 FY15 (OE)* FY15 (RE)* FY16 (E)
Net Sales 42480 46765 54169 56820 65059
Operating Profit 6010 7466 8559 8559 10247
Adjusted PAT 4053 4850 5525 5525 6669
EPS 6.3 7.5 8.6 8.6 10.3
OPM (%) 14.1 16.0 15.8 15.1 15.8
NPM (%) 9.5 10.4 10.2 9.7 10.3
PE 42.2 35.3 31.0 31.0 25.7
*OE = Original Estimates; RE = Revised Estimates (Source: Company, HDFC sec Estimates)
RETAIL RESEARCH Page | 5
Analyst: Mehernosh K. Panthaki – IT, FMCG & Midcaps; Email ID: mehernosh.panthaki@hdfcsec.com
RETAIL RESEARCH Tel: (022) 3075 3400 Fax: (022) 2496 5066 Corporate Office
HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022)
2496 5066 Website: www.hdfcsec.com Email: hdfcsecretailresearch@hdfcsec.com
Disclaimer: This document has been prepared by HDFC Securities Limited and is meant for sole use by the recipient and not for circulation. This document is not to be reported or copied or made available to
others. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. The information contained herein is from sources believed reliable. We do not represent that it is accurate or
complete and it should not be relied upon as such. We may have from time to time positions or options on, and buy and sell securities referred to herein. We may from time to time solicit from, or perform investment
banking, or other services for, any company mentioned in this document. This report is intended for non-Institutional Clients

More Related Content

What's hot

Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17Profarma
 
2015 annual results announcement
2015 annual results announcement2015 annual results announcement
2015 annual results announcementPranav Rao
 
April/May 2018 Investor Presentation
April/May 2018 Investor PresentationApril/May 2018 Investor Presentation
April/May 2018 Investor Presentationingersollrand2016
 
P&G Delivers 15% Earnings Per Share Growth for Fiscal Year
P&G Delivers 15% Earnings Per Share Growth for Fiscal YearP&G Delivers 15% Earnings Per Share Growth for Fiscal Year
P&G Delivers 15% Earnings Per Share Growth for Fiscal Yearfinance3
 
2018 UBS Global Industrials and Transportation Conference Presentation
2018 UBS Global Industrials and Transportation Conference Presentation2018 UBS Global Industrials and Transportation Conference Presentation
2018 UBS Global Industrials and Transportation Conference Presentationingersollrand2016
 
May 2018 investor presentation
May 2018 investor presentationMay 2018 investor presentation
May 2018 investor presentationingersollrand2016
 
Tnc q1 2017_earnings_presentation_final
Tnc q1 2017_earnings_presentation_finalTnc q1 2017_earnings_presentation_final
Tnc q1 2017_earnings_presentation_finalTennantCorporation
 
2016 interim results mengniu
2016 interim results   mengniu2016 interim results   mengniu
2016 interim results mengniuPranav Rao
 
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...finance3
 
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growth
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit GrowthP&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growth
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growthfinance3
 
Investor presentation may 2017
Investor presentation may 2017Investor presentation may 2017
Investor presentation may 2017TennantCorporation
 
Arvnd 20150205-mosl-ru-pg014
Arvnd 20150205-mosl-ru-pg014Arvnd 20150205-mosl-ru-pg014
Arvnd 20150205-mosl-ru-pg014Jigar Savla
 
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...finance3
 
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook finance3
 
TOG Oppday 60Q1 17/05/2017
TOG Oppday 60Q1 17/05/2017TOG Oppday 60Q1 17/05/2017
TOG Oppday 60Q1 17/05/2017Share Rora
 
Litmus Case Study Competition
Litmus Case Study CompetitionLitmus Case Study Competition
Litmus Case Study CompetitionNitesh Luthra
 
P&G Delivers Double-Digit Sales Growth in First Quarter
P&G Delivers Double-Digit Sales Growth in First QuarterP&G Delivers Double-Digit Sales Growth in First Quarter
P&G Delivers Double-Digit Sales Growth in First Quarterfinance3
 
Afm nroi project ppt
Afm nroi project pptAfm nroi project ppt
Afm nroi project pptAnoop Sharma
 
2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 ResultsKappAhl
 
Barry Callebaut Annual Results 2016/17
Barry Callebaut Annual Results 2016/17Barry Callebaut Annual Results 2016/17
Barry Callebaut Annual Results 2016/17Barry Callebaut
 

What's hot (20)

Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
2015 annual results announcement
2015 annual results announcement2015 annual results announcement
2015 annual results announcement
 
April/May 2018 Investor Presentation
April/May 2018 Investor PresentationApril/May 2018 Investor Presentation
April/May 2018 Investor Presentation
 
P&G Delivers 15% Earnings Per Share Growth for Fiscal Year
P&G Delivers 15% Earnings Per Share Growth for Fiscal YearP&G Delivers 15% Earnings Per Share Growth for Fiscal Year
P&G Delivers 15% Earnings Per Share Growth for Fiscal Year
 
2018 UBS Global Industrials and Transportation Conference Presentation
2018 UBS Global Industrials and Transportation Conference Presentation2018 UBS Global Industrials and Transportation Conference Presentation
2018 UBS Global Industrials and Transportation Conference Presentation
 
May 2018 investor presentation
May 2018 investor presentationMay 2018 investor presentation
May 2018 investor presentation
 
Tnc q1 2017_earnings_presentation_final
Tnc q1 2017_earnings_presentation_finalTnc q1 2017_earnings_presentation_final
Tnc q1 2017_earnings_presentation_final
 
2016 interim results mengniu
2016 interim results   mengniu2016 interim results   mengniu
2016 interim results mengniu
 
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...
P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, b...
 
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growth
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit GrowthP&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growth
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growth
 
Investor presentation may 2017
Investor presentation may 2017Investor presentation may 2017
Investor presentation may 2017
 
Arvnd 20150205-mosl-ru-pg014
Arvnd 20150205-mosl-ru-pg014Arvnd 20150205-mosl-ru-pg014
Arvnd 20150205-mosl-ru-pg014
 
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...
 
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook
 
TOG Oppday 60Q1 17/05/2017
TOG Oppday 60Q1 17/05/2017TOG Oppday 60Q1 17/05/2017
TOG Oppday 60Q1 17/05/2017
 
Litmus Case Study Competition
Litmus Case Study CompetitionLitmus Case Study Competition
Litmus Case Study Competition
 
P&G Delivers Double-Digit Sales Growth in First Quarter
P&G Delivers Double-Digit Sales Growth in First QuarterP&G Delivers Double-Digit Sales Growth in First Quarter
P&G Delivers Double-Digit Sales Growth in First Quarter
 
Afm nroi project ppt
Afm nroi project pptAfm nroi project ppt
Afm nroi project ppt
 
2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results
 
Barry Callebaut Annual Results 2016/17
Barry Callebaut Annual Results 2016/17Barry Callebaut Annual Results 2016/17
Barry Callebaut Annual Results 2016/17
 

Similar to Marico: Q1FY15 numbers above estimates, maintain buy - HDFC Sec

MindTree: Rupee appreciation drags revenue growth during Q1FY15
MindTree: Rupee appreciation drags revenue growth during Q1FY15MindTree: Rupee appreciation drags revenue growth during Q1FY15
MindTree: Rupee appreciation drags revenue growth during Q1FY15IndiaNotes.com
 
TCS Q1FY15: Results in-line, buy on dips
TCS Q1FY15: Results in-line, buy on dipsTCS Q1FY15: Results in-line, buy on dips
TCS Q1FY15: Results in-line, buy on dipsIndiaNotes.com
 
Dabur Q3FY15: Mixed quarter; maintain neutral
 Dabur Q3FY15: Mixed quarter; maintain neutral Dabur Q3FY15: Mixed quarter; maintain neutral
Dabur Q3FY15: Mixed quarter; maintain neutralIndiaNotes.com
 
Dabur India Q1FY15: Maintain neutral
 Dabur India Q1FY15: Maintain neutral Dabur India Q1FY15: Maintain neutral
Dabur India Q1FY15: Maintain neutralIndiaNotes.com
 
Vivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationVivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationJigar Savla
 
Dabur Q4FY14 results in line with expectations by Motilal Oswal
Dabur Q4FY14 results in line with expectations by Motilal OswalDabur Q4FY14 results in line with expectations by Motilal Oswal
Dabur Q4FY14 results in line with expectations by Motilal OswalIndiaNotes.com
 
FLFLInvestor_PPT_Q3FY19.pdf
FLFLInvestor_PPT_Q3FY19.pdfFLFLInvestor_PPT_Q3FY19.pdf
FLFLInvestor_PPT_Q3FY19.pdfSanketPingale12
 
Stock Advisory for Today - Natural View on the Stock JSW Steel LTD, Marico a...
Stock Advisory for Today -  Natural View on the Stock JSW Steel LTD, Marico a...Stock Advisory for Today -  Natural View on the Stock JSW Steel LTD, Marico a...
Stock Advisory for Today - Natural View on the Stock JSW Steel LTD, Marico a...NARNOLIA SECURITIES LIMITED
 
LIC Housing Finance Q1FY15: Buy for a target of Rs332
 LIC Housing Finance Q1FY15: Buy for a target of Rs332 LIC Housing Finance Q1FY15: Buy for a target of Rs332
LIC Housing Finance Q1FY15: Buy for a target of Rs332IndiaNotes.com
 
Global Digital Transformation Partner 2019
Global Digital Transformation Partner 2019Global Digital Transformation Partner 2019
Global Digital Transformation Partner 2019Mr Nyak
 
Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralIndiaNotes.com
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldIndiaNotes.com
 
ITC Q1FY15 results in line with estimates; buy - HDFC Sec
ITC Q1FY15 results in line with estimates; buy - HDFC SecITC Q1FY15 results in line with estimates; buy - HDFC Sec
ITC Q1FY15 results in line with estimates; buy - HDFC SecIndiaNotes.com
 
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; Hold
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; HoldHindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; Hold
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; HoldIndiaNotes.com
 
Gcpl 1 qfy2015ru_310714
Gcpl 1 qfy2015ru_310714Gcpl 1 qfy2015ru_310714
Gcpl 1 qfy2015ru_310714Bhavnesh Mutha
 
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 Q3FY15 Recommendation: Maintain hold on Alembic Pharma Q3FY15 Recommendation: Maintain hold on Alembic Pharma
Q3FY15 Recommendation: Maintain hold on Alembic PharmaIndiaNotes.com
 
Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16choice broking
 
Hdfc securities wipro_29_oct_2014
Hdfc securities wipro_29_oct_2014Hdfc securities wipro_29_oct_2014
Hdfc securities wipro_29_oct_2014IndiaNotes.com
 
Tnc q4 2015_earnings_presentation_final
Tnc q4 2015_earnings_presentation_finalTnc q4 2015_earnings_presentation_final
Tnc q4 2015_earnings_presentation_finalTennantCorporation
 

Similar to Marico: Q1FY15 numbers above estimates, maintain buy - HDFC Sec (20)

MindTree: Rupee appreciation drags revenue growth during Q1FY15
MindTree: Rupee appreciation drags revenue growth during Q1FY15MindTree: Rupee appreciation drags revenue growth during Q1FY15
MindTree: Rupee appreciation drags revenue growth during Q1FY15
 
TCS Q1FY15: Results in-line, buy on dips
TCS Q1FY15: Results in-line, buy on dipsTCS Q1FY15: Results in-line, buy on dips
TCS Q1FY15: Results in-line, buy on dips
 
Dabur Q3FY15: Mixed quarter; maintain neutral
 Dabur Q3FY15: Mixed quarter; maintain neutral Dabur Q3FY15: Mixed quarter; maintain neutral
Dabur Q3FY15: Mixed quarter; maintain neutral
 
Dabur India Q1FY15: Maintain neutral
 Dabur India Q1FY15: Maintain neutral Dabur India Q1FY15: Maintain neutral
Dabur India Q1FY15: Maintain neutral
 
Vivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationVivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 Presentation
 
Dabur Q4FY14 results in line with expectations by Motilal Oswal
Dabur Q4FY14 results in line with expectations by Motilal OswalDabur Q4FY14 results in line with expectations by Motilal Oswal
Dabur Q4FY14 results in line with expectations by Motilal Oswal
 
FLFLInvestor_PPT_Q3FY19.pdf
FLFLInvestor_PPT_Q3FY19.pdfFLFLInvestor_PPT_Q3FY19.pdf
FLFLInvestor_PPT_Q3FY19.pdf
 
Stock Advisory for Today - Natural View on the Stock JSW Steel LTD, Marico a...
Stock Advisory for Today -  Natural View on the Stock JSW Steel LTD, Marico a...Stock Advisory for Today -  Natural View on the Stock JSW Steel LTD, Marico a...
Stock Advisory for Today - Natural View on the Stock JSW Steel LTD, Marico a...
 
LIC Housing Finance Q1FY15: Buy for a target of Rs332
 LIC Housing Finance Q1FY15: Buy for a target of Rs332 LIC Housing Finance Q1FY15: Buy for a target of Rs332
LIC Housing Finance Q1FY15: Buy for a target of Rs332
 
Global Digital Transformation Partner 2019
Global Digital Transformation Partner 2019Global Digital Transformation Partner 2019
Global Digital Transformation Partner 2019
 
Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; Neutral
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
 
ITC Q1FY15 results in line with estimates; buy - HDFC Sec
ITC Q1FY15 results in line with estimates; buy - HDFC SecITC Q1FY15 results in line with estimates; buy - HDFC Sec
ITC Q1FY15 results in line with estimates; buy - HDFC Sec
 
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; Hold
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; HoldHindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; Hold
Hindustan Unilever Q4FY15: Net sales up 9% y/y to Rs7,555cr; Hold
 
Gcpl 1 qfy2015ru_310714
Gcpl 1 qfy2015ru_310714Gcpl 1 qfy2015ru_310714
Gcpl 1 qfy2015ru_310714
 
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 Q3FY15 Recommendation: Maintain hold on Alembic Pharma Q3FY15 Recommendation: Maintain hold on Alembic Pharma
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 
Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16
 
Hdfc securities wipro_29_oct_2014
Hdfc securities wipro_29_oct_2014Hdfc securities wipro_29_oct_2014
Hdfc securities wipro_29_oct_2014
 
Gxl investor preso
Gxl investor presoGxl investor preso
Gxl investor preso
 
Tnc q4 2015_earnings_presentation_final
Tnc q4 2015_earnings_presentation_finalTnc q4 2015_earnings_presentation_final
Tnc q4 2015_earnings_presentation_final
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 

Marico: Q1FY15 numbers above estimates, maintain buy - HDFC Sec

  • 1. RETAIL RESEARCH Page | 1 HDFC sec Scrip code Industry CMP (Rs.) Recommended Action Averaging Price Band (Rs.) Target (Rs.) Time Horizon MARINDEQNR FMCG 265.4 Buy at CMP and add on dips 238‐248 295 1 quarter In our Q4FY14 Result Update dated May 10, 2014, we had recommended investors to buy Marico on dips to Rs. 214‐223 for a price target of Rs. 248 over the next quarter. Thereafter the stock touched a low of Rs. 222.1 on May 20, 2014 and subsequently met our price target on May 27, 2014. It touched a new high of Rs. 294.5 on Aug 05, 2014. Currently, it is quoting at Rs. 265.4. Marico’s ex Kaya numbers for Q1FY15 were above our estimates on the revenue front, while operating profit & PAT growth were in line. We present an update on the stock: Q1FY15 Results Review (Consolidated – Ex Kaya) Y‐o‐Y • The consolidated net sales increased by 25.2% to Rs. 16192.4 mn, driven by price hikes taken across the portfolio to cover a major part of the input cost push. Volume growth stood at 5%. The domestic consumer product business grew by 28% with volume growth of 6.5%. Parachute’s rigid portfolio (packs in blue bottles) recorded value growth of 41%, with volume growth of 6% (lower than 10% volume growth reported in Q4FY14, but better than 4% growth in Q1FY14). Saffola grew by 14%, largely driven by healthy volume growth of 10%. Value added hair oil (VAHO) grew by 28%, with volume growth recovering to 11% (compared to 5% in Q4FY14 & 8% volume growth in Q3). However, Paras brands disappointed with flat revenue growth. The company registered market share gains in more than 80% of the portfolio. • International business posted growth of 16.3% aided by 6.7% translation gains. Constant currency growth stood at 9.6%. Growth in the Core markets remained healthy with Bangladesh growing at 14%, MENA at 18% and South Africa at 9% on constant currency basis. However, Vietnam remained flat during the quarter. • Gross margins fell sharply by 382 bps Y‐o‐Y to 45.2% on the back of steep rise in copra prices (up 131% Y‐o‐Y). Also, the market prices of liquid paraffin were 14% higher Y‐o‐Y. However, fall in EBITDA margins was limited at 70 bps Y‐o‐Y to 16.5%, aided by relatively lower growth in A&P cost & other expenses (up 13% & 11.1% respectively). On absolute basis, the operating profit increased by 20.1% Y‐o‐Y. • PAT grew by 19.5% Y‐o‐Y, impacted by higher tax rate (up 253 bps Y‐o‐Y) & higher depreciation cost (up 27.3% Y‐o‐Y). PAT margins fell by 55 bps Y‐o‐Y to 11.4%. EPS for the quarter stood at Rs. 2.9 vs Rs. 2.4 in Q1FY14. Q‐o‐Q • Sequentially, the results were impressive. Net Sales grew by 51.4%, while operating profit rose 72.8% Q‐o‐Q, aided by relatively lower growth in employee & A&P cost (up 31.2% & 9.8% Q‐o‐Q respectively). OPM increased by 205 bps Q‐o‐Q from 14.4% in Q4FY14. • PAT grew by 108.7%, aided by marginal growth in interest cost (4.3% Q‐o‐Q, decline in the depreciation expense (down 5.5% Q‐o‐Q) & lower effective tax rate (down 770 bps Q‐o‐Q). PAT margins improved by 315 bps Q‐o‐Q from 8.3% in Q4FY14. RETAIL RESEARCH Aug 11, 2014Marico Ltd. – Q1FY15 Result Update
  • 2. RETAIL RESEARCH Page | 2 Quarterly Financials: Consolidated (ex‐ Kaya) (Rs. in Million) Particulars Q1FY15 Q1FY14 VAR [%] Q4FY14 VAR [%] Remarks Net Sales 16192.4 12930 25.2 10698.2 51.4 • The overall growth was driven by price hikes taken across the portfolio to cover a major part of the input cost push. Volume growth stood at 5%. The domestic consumer product business grew by 28%, led by strong value growth in Parachute and VAHO (up 41% & 28% Y‐o‐Y respectively. • International business grew by 16.3% aided by 6.7% translation gains. Constant currency growth stood at 9.6% with healthy growth (in CC) across key markets like Bangladesh (up 14%), MENA (at 18%) and South Africa (up 9%). Other Operating Income 38.9 30 29.7 22.4 73.7 Total Operating Income 16231.3 12960 25.2 10720.6 51.4 Total Expenditure 13564.8 10740 26.3 9177.9 47.8 Raw Material Consumed 7863.9 5580 40.9 6005.3 30.9 The material cost to net sales rose 383 bps Y‐o‐Y & 271 bps Q‐o‐Q to 55%. Gross margins fell sharply on the back of steep rise in copra prices (up 131% Y‐o‐Y). Also, prices of Liquid Paraffin were up 14% Y‐o‐Y. Stock Adjustment 730.9 740 ‐1.2 ‐697.1 ‐204.9 Purchase of Finished Goods 316.1 300 5.4 289 9.4 Employee Expenses 854.5 730 17.1 651.3 31.2 Advertisement & Sales Promotion 1921.8 1700 13.0 1219.1 57.6 ASP cost / Net Sales fell by 128 bps Y‐o‐Y, but rose 47 bps Q‐o‐Q to 11.4%. The Y‐o‐Y fall was due to high inflation led topline growth. The Company expects to operate in a band of 11‐12% in the medium term. Other Expenses 1877.6 1690 11.1 1710.3 9.8 Operating Profit 2666.4 2220 20.1 1542.7 72.8 Other Income 183.2 140 30.9 128.4 42.7 Interest 70.4 100 ‐29.6 67.5 4.3 PBDT 2779.3 2260 23.0 1603.6 73.3 Depreciation 203.7 160 27.3 215.5 ‐5.5 Y‐o‐Y rise in depreciation cost was due to adoption of the useful life of fixed assets as per Schedule II of Companies Act 2013, effective April 1, 2014 (Rs.2.65 cr), fixed asset additions made during the year and impairment of fixed assets in Egypt and Bangladesh. PBT 2575.5 2100 22.6 1388.1 85.5 Tax (incl. DT & FBT) 678.5 500 35.7 472.6 43.6 The effective tax rate on PBT increased by 253 bps Y‐o‐Y, but fell by 770 bps Q‐o‐Q to 26.3%. The Y‐o‐Y rise in the ETR is primarily due to one of the factories in India going out of tax exemption and another is moving into 30% exemption bracket from 100% exemption. Also, from this year, there has been an increase in tax rate in Vietnam. The expected ETR during FY15 and FY16 could be around 28‐29%. PAT (before minority interest) 1897.0 1600 18.6 915.5 107.2 Minority Interest 44.2 50 ‐11.5 27.9 58.6 PAT (net of minority interest) 1852.8 1550 19.5 887.6 108.7 Y‐o‐Y PAT growth was lower than the sales growth, impacted by lower OPM, higher depreciation cost & higher effective tax rates.
  • 3. RETAIL RESEARCH Page | 3 EPS (Rs.) 2.9 2.4 19.5 1.4 108.7 Equity 644.9 644.8 0.0 644.9 0.0 FV 1.0 1.0 0.0 1.0 0.0 OPM (%) 16.5 17.2 ‐4.1 14.4 14.2 EBITDA margins contraction was limited at 70 bps Y‐o‐Y to 16.5%, helped by relatively lower growth in A&P cost & other expenses. While the overall margins contracted, the OPM of international business improved by 490 bps to 18.2% reflecting a structural shift in international margins based on the cost management projects undertaken last year. PATM (%) 11.4 12.0 ‐4.5 8.3 37.9 (Source: Company, HDFC sec) Other Developments / Highlights • The non‐focused part of the parachute portfolio (pouch packs) witnessed de‐growth as input prices faced inflationary pressures while the Company maintained minimum threshold margins. It is generally observed that an inflationary environment swings the competitive position to the Company's advantage as it puts pressure on the working capital requirements of marginal players. During the 12 months ended June 2014, Parachute along with Nihar increased its market share by 50bps to 56%. Parachute's share in the rural markets, in the range of 35‐40%, is lower than that in the urban markets, thus providing potential headroom for growth. • Market share of Saffola declines 200bps Y‐o‐Y to 55%, thus indicating increased competitive intensity. However, Saffola Oats has emerged as a strong no.2 brand in the oats category with a value market share of 17%. Two sweet flavours with fruits were introduced to compliment the bouquet of six savory flavors. Focus on value added offerings in the oats segment has enabled the Company to capture 51% share in the flavored oats market. The Company launched a new campaign on Masala Oats this quarter, the initial response to which has been very positive. The Company expects to reach a top line of ~Rs 70‐75 crore (USD 12‐13 mn) in this fiscal for the franchise and is poised to cross Rs. 1 bn (USD 17 mn) landmark next year. • In VAHO, the company continues to grow faster than the market and has emerged as a clear market leader with 28% share (for 12 months ended June 2014) as against 27% during the same period last year. Nihar Shanti Amla continues to gain market share and achieved a volume market share of about 30% for the 12 months ended June 2014 in the Amla hair oils category (MAT Q1FY14: 27%). • Sales in Modern Trade (9% of the domestic turnover) continued its good run and grew by 27%. Rural growth (33% Y‐o‐Y) continues to outperform urban (25% Y‐o‐Y) as rural now contributes 30% to total domestic sales. • As per the management, its key focus in the current scenario would be on improving volume growth over profitability. It has guided for 7‐8% volume growth and 14.5‐ 15% EBITDA margin band for FY15 though it expects next two quarters to witness margin pressure on account of sustained copra inflation. • Due to a spurt in copra prices from mid‐2013 onwards, the company has initiated a series of price increases. A weighted average price increase of 19% over Q4FY14 was taken during the quarter. This, coupled with price increases taken last year, has led to a weighted average price increase of 33%. The given price increases would partially offset the rise in copra prices. • The company plans to double its revenues over the next four years driven by a mix of organic and inorganic growth. It plans to become an emerging market MNC with focus on Asia and Africa in key categories of hair care, skin nourishment and male grooming. It has identified give key areas of transformation—innovation, GTM, Talent Value Proposition, IT & Analytics and Cost Management.
  • 4. RETAIL RESEARCH Page | 4 Conclusion & Recommendation: Marico’s ex Kaya numbers for Q1FY15 were above our estimates on the revenue front, while operating profit & PAT growth were in line. The growth was largely led by price hikes taken across the portfolio to cover a major part of the input cost push. Volume growth stood at 5%. Strong growth in domestic consumer product business (up 28% Y‐o‐Y, aided by strong value growth in parachute and VAHO) and decent growth in international business revenues (led by double digit growth in Bangladesh & MENA) despite challenging environment was encouraging. Further, the volume growth recovery in domestic business witnessed in Q4FY14 was sustained in Q1FY15 despite challenging environment (though in single digits). On the profit front, while the sharp contraction in gross margins (down 382 bps Y‐o‐Y), impacted by steep rise in copra prices was discomforting, the overall OPM contraction was limited (at 70 bps Y‐o‐Y), aided by relatively lower growth in A&P cost & other expenses. We expect volume growth of Parachute (rigid pack) to improve gradually from 6% (which was healthy in our view considering steep rise in copra prices) to 7‐8% in the coming quarters, likely to be driven by conversion from loose coconut oil to branded coconut oil and rural market share gains. We feel that an inflationary environment swings the competitive position to the company’s advantage as it puts pressure on the working capital requirements of marginal regional players. This leads to market share gain and better volume growth. While volume growth recovery in VAHO (compared to Q3FY14 & Q4FY14) is encouraging, its sustainability is essential. With company’s efforts to increase the distribution reach in rural market and shift in consumer preference towards living a healthy lifestyle, we expect Saffola’s volume growth to remain healthy in double digits (expected to improve gradually from 10% currently). Sharp rise in the Copra prices would continue to put pressure on Marico’s overall gross margins in near to medium term. However, price hikes initiated in parachute (weighted average price increase of 33% Y‐o‐Y) and in VAHO (weightage average price hikes of 6% Y‐o‐Y across portfolio) would restrict a sharp deceleration in margins. Further, cost rationalisation would limit the contraction in OPM in FY15. However, we expect gradual uptick in margins in FY16, since we expect stability in Copra prices. We feel Marico could surpass our revenue estimates in FY15. Hence we are enhancing the same by 4.9%. However, it seems to be on track to meet our operating profit & PAT growth. Hence we are keeping the same unchanged (since margins could be lower than our expectations). We have incorporated projections for FY16, wherein we expect net sales, operating profit & PAT to grow by 16%, 19.7% & 20.8% respectively. At the CMP, Marico trades at 25.7xFY16E EPS. Sustained improvement in the volume growth (which is a key driver for sustainable profit growth), market share gains & profitability could result in gradual re‐rating in the stock price in the coming quarters. Valuing the stock at 28.5xFY16E EPS we arrive at a price target of Rs. 295. We feel investors could buy the stock at current levels and average it on dips to Rs. 238‐248 (23‐24xFY16E EPS) band for our price target over the next quarter. Financial Estimations: (Consolidated) ‐ excluding Kaya. (Rs. in Million) Particulars FY13 FY14 FY15 (OE)* FY15 (RE)* FY16 (E) Net Sales 42480 46765 54169 56820 65059 Operating Profit 6010 7466 8559 8559 10247 Adjusted PAT 4053 4850 5525 5525 6669 EPS 6.3 7.5 8.6 8.6 10.3 OPM (%) 14.1 16.0 15.8 15.1 15.8 NPM (%) 9.5 10.4 10.2 9.7 10.3 PE 42.2 35.3 31.0 31.0 25.7 *OE = Original Estimates; RE = Revised Estimates (Source: Company, HDFC sec Estimates)
  • 5. RETAIL RESEARCH Page | 5 Analyst: Mehernosh K. Panthaki – IT, FMCG & Midcaps; Email ID: mehernosh.panthaki@hdfcsec.com RETAIL RESEARCH Tel: (022) 3075 3400 Fax: (022) 2496 5066 Corporate Office HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Website: www.hdfcsec.com Email: hdfcsecretailresearch@hdfcsec.com Disclaimer: This document has been prepared by HDFC Securities Limited and is meant for sole use by the recipient and not for circulation. This document is not to be reported or copied or made available to others. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. The information contained herein is from sources believed reliable. We do not represent that it is accurate or complete and it should not be relied upon as such. We may have from time to time positions or options on, and buy and sell securities referred to herein. We may from time to time solicit from, or perform investment banking, or other services for, any company mentioned in this document. This report is intended for non-Institutional Clients